China NMPA accepts Akeso's sNDA penpulimab combination therapy for first-line treatment of hepatocellular carcinoma: Hong Kong Monday, November 25, 2024, 13:00 Hrs [IST] Akeso, In ...
Some results have been hidden because they may be inaccessible to you